Tag:

Insmed

Latest Headlines

Latest Headlines

UPDATED: Insmed faces another setback as lead therapy flunks PhII lung study

Insmed is once again hustling to put the best spin possible on a clinical study of its only therapy. But faced with a row of skeptical analysts, it's not likely to make much headway.

Siemens CEO Peter Löscher ousted amid revenue struggle

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email |...

Insmed shares routed on head-to-head antibiotic Phase III results

Bright and early this morning Insmed ($INSM) announced that its inhaled antibiotic Arikace hit its primary endpoint in a Phase III study and was awarded fast-track status at the FDA.

Bayer exec takes reins at J&J's troubled consumer products biz

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and Nesa Nourmohammadi (...

Insmed stock soars after FDA ends hold on key lung drug

The company's stock price skyrocketed nearly 63% to $4.40 per share as of 12:07 p.m. ET after the announcement.

Insmed shares spike after FDA lifts hold

Shares of Insmed ($INSM) shot up on Friday after the company reported that the FDA has lifted a clinical hold on its trial of Arikace, an inhalable antibiotic for lung disease. Regulators had stepped

Insmed shares nosedive as regulators demand tox study on PhIII drug

Insmed's regulatory woes with the cystic fibrosis drug Arikace are continuing this morning with the news that the FDA will not release its hold on the late-stage trial for the treatment and is now

Insmed shares crater as FDA puts a clamp on Ph3 CF study

Just seven months after completing its takeover of Transave, Insmed is reporting that the FDA has put a clinical hold on the Phase III trial of Arikace, a late-stage cystic fibrosis drug that had

Insmed shares tank on mid-stage trial failure

Insmed's lead drug failed to show efficacy in a mid-stage clinical trial of a genetic condition called myotonic muscular dystrophy and investors swiftly hammered the stock, sending down shares more

Insmed drug OK'd for ALS patients, new trial

The FDA and Insmed have hammered out a deal that will allow a limited number of patients with Lou Gehrig's disease to receive doses of Iplex. That drug is approved for growth hormone deficiency but